696 related articles for article (PubMed ID: 34244052)
41. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer.
Ponzone R; Montemurro F; Maggiorotto F; Robba C; Gregori D; Jacomuzzi ME; Kubatzki F; Marenco D; Dominguez A; Biglia N; Sismondi P
Ann Oncol; 2006 Nov; 17(11):1631-6. PubMed ID: 16980602
[TBL] [Abstract][Full Text] [Related]
43. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
[TBL] [Abstract][Full Text] [Related]
44. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
[TBL] [Abstract][Full Text] [Related]
45. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
46. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
47. p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
[TBL] [Abstract][Full Text] [Related]
48. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
49. Negative estrogen receptors and positive progesterone receptors breast cancers.
Delvallée J; Etienne C; Arbion F; Vildé A; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2021 Feb; 50(2):101928. PubMed ID: 33022450
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
[TBL] [Abstract][Full Text] [Related]
51. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
52. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Lambertini M; Campbell C; Gelber RD; Viale G; McCullough A; Hilbers F; Korde LA; Werner O; Chumsri S; Jackisch C; Wolff AC; Vaz-Luis I; Ferreira AR; Prat A; Moreno-Aspitia A; Piccart M; Loi S; de Azambuja E
Breast Cancer Res Treat; 2019 Aug; 177(1):103-114. PubMed ID: 31134488
[TBL] [Abstract][Full Text] [Related]
53. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
54. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
[TBL] [Abstract][Full Text] [Related]
55. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
56. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
[TBL] [Abstract][Full Text] [Related]
57. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
58. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
59. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
60. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Onitilo AA; Engel JM; Greenlee RT; Mukesh BN
Clin Med Res; 2009 Jun; 7(1-2):4-13. PubMed ID: 19574486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]